biowa,
However, the invention description calls out a very specific set of antibodies:
But the claim seems much broader - it's not even limited to NHL:
Also, the invention is not limited to the CD19 and CD20 antibodies. Rather, the invention encompasses the use of antibodies which are identify antigens associated with cells of the B cell lineage to treat cancers which are clonal from such cells. Examples of such antibodies are B2, B3, B4 (HD-237), and J5, in addition to B1. Examples of such cancers are ALL, CLL, Hairy Cell leukemia, and chronic myeloblastic leukemias in a blast crisis stage, in addition to lymphomas.
It may well be that ZEV isn't covered specifically - IDPH could still get a valid patent for it, but it would be one that was dominated by the new CLTR patent.
Peter (very much not a patent lawyer, so normal disclaimers get amplified here). |
